Montana has cleared the path for a radically accelerated drug evaluation system, allowing biotech firms to secure state approval for therapeutics tested on as few as 10 healthy individuals.
The $12,500 State Review Board Mechanism
The state’s freshly established regulatory pathway lets biotech companies sidestep traditional clinical pipelines if their compounds have cleared basic preliminary testing.
Reporting by Jessica Hamzelou details the mechanics: firms pay a $12,500 fee to submit drug candidates directly to a newly minted state review board. For high-velocity developers and the radical longevity community, the route offers unmatched speed. For institutional pharmacologists, however, it signals a dangerous departure from standard evaluation protocols.
Collapsing Traditional Trials Into Tiny Cohorts
The Desperate Search for Rare Disease Cures
Kris DeVault knows this urgency intimately. His son, Brody, was born in March 2023 and subsequently diagnosed with creatine transporter deficiency—a devastating condition that robs the brain and muscles of the metabolic energy needed for basic cellular development.
Zero FDA-approved cures exist for Brody. In response, DeVault tracked down a developer working on an experimental asset designed to target the metabolic deficit. Yet that candidate remains stuck in early-stage pipelines, tested only in animal models and a microscopic cohort of healthy adult volunteers. Standard clinical pathways slam the door shut, leaving institutional doctors legally powerless to write a prescription.
Autonomy Versus Institutional Oversight
DeVault is realistic, acknowledging the unproven drug might fail completely. Even so, his pursuit highlights why right-to-try legislation commands fierce loyalty among affected families. When strict clinical trial criteria lock out desperate patients, state-level experimental pathways offer a rare exit ramp.
Critics warn that bypassing standardized evaluation boards effectively turns vulnerable citizens into unwitting test subjects. Proponents argue the opposite: that terminal patients deserve absolute bodily autonomy, provided they offer informed consent and shoulder the financial burden. As Montana prepares to open its experimental clinics, the clash between strict bioethical standards and profound patient desperation enters uncharted territory.
